PHILADELPHIA and LONDON (PRWEB) December 18, 2017
Enterprise implementation of clinical technology solutions was easily the most discussed theme at the 2017 DrugDev Summit, co-chaired by Novartis and CSL Behring last month in Philadelphia. More than 125 of the industry’s most forward-thinking executives from approximately 50 sponsors and sites gathered for two days to share their experiences using the DrugDev Spark™ clinical operations suite, highlighted by case studies, best practices, challenges and hopes for the future.
The event featured inspirational keynotes, hands-on product workshops, engaging deep-dive discussions on hot-button clinical trial issues, and first looks at new and upcoming DrugDev Spark solutions. Presentations were delivered by companies including Allergan, Alnylam Pharmaceuticals, Amgen, Bayer, Boehringer-Ingelheim, CSL Behring, Janssen, Karyopharm Therapeutics, Meridien Research, Novartis, and Roche, along with several site representatives.
Some of the more popular topics included…
The business case for enterprise implementations of the DrugDev Spark clinical operations suite at three Top 10 pharmaceutical companies
- How one company integrated systems and processes to achieve transformational change and unlock the power of clinical researchers worldwide
- Dispelling myths of electronic informed patient consent (eConsent), and why it is rapidly increasing in adoption around the world
- The DrugDev Spark roadmap and how it drives IQVIA clinical technology
- How shared data sources and cross-company collaboration enables informed site selection decisions
- Why site payments represent the most boring (and important) success factor for sites
- How the unified integrated site activation and engagement solutions on DrugDev Spark helped one sponsor beat its enrollment timelines and goals
Attendees also were riveted by a keynote from Daniel DeFabio and Bo Bigelow, producers of “Disorder: The Rare Disease Film Festival.” The pair of passionate and committed rare disease advocates shared their personal stories and how they created a film movement and event that drew hundreds of researchers and patients to Boston in October. Currently they are seeking to capture, collect and curate at least one film for every rare disease currently identified as part of their “7,000 Films Wanted” initiative. To learn more, visit https://www.rarediseasefilmfestival.com/7000-films-wanted
From the educational sessions and thought-provoking deep dives to the social networking opportunities and hands-on DrugDev Spark product workshops, feedback from attendees was overwhelmingly positive. Comments from a post-event feedback survey included…
“The DrugDev Summit was a great experience! I enjoyed meeting folks from DrugDev, and enjoyed learning about enterprise solutions. It was extremely informative, and fun too.” – Patrick Lynch, Site Payments Manager, Karyopharm Therapeutics
“It was great. I learned a lot and am excited to share my learnings with the rest of my department. I think there's a lot for us to think about in terms of how DrugDev Spark can make everything easier and more efficient.” – Lauren Alves, Senior Clinical Trial Manager, Alnylam Pharmaceuticals
“As a site, the DrugDev Summit was a great opportunity for my organization to provide practical feedback about clinical trial technology application and value, while gaining insight about how sponsors and CROs make decisions regarding the use of such technology. I was honored to be invited and to share my perspective.” – Kelly Toms, Business Development Manager, Meridien Research
Added Kristopher Sarajian, DrugDev Vice President of Marketing, “The DrugDev Summit is the highlight of our year – where else can we have such a dedicated and exclusive opportunity to meet and socialize with over 125 customers who are leading the ongoing change movement in clinical research? I’m still amazed that it continues to grow larger than many industry conferences, and I’m honored so many people find our Summit to be such a productive use of their time. It’s a testament not only to the personal relationships DrugDev maintains with its customers, but also to the value of the presentations, open discussions and unfiltered feedback led by attendees. Each year, the Summit gets better and better because customers and sites continue to share their results of their innovative use of technology like DrugDev Spark, and I can’t wait to see what they accomplish next.”
DrugDev, an IQVIA company, helps the world do more trials through industry-wide collaboration, standardization and a beautiful technology experience. DrugDev Spark™, the unified clinical operations suite, is comprised of proven solutions used by 85 sponsors and CROs on over 2,000 clinical trials to transform the quality and efficiency of clinical trials from startup through closeout. DrugDev Spark is powered by the DrugDev Golden Number, the award-winning universal identifier for global site facilities and investigators used by TransCelerate and the Investigator Databank. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust DrugDev by scheduling a demo of DrugDev Spark at drugdev.com.
Read the full story at http://www.prweb.com/releases/2017/12/prweb15012944.htm